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Background: Bone Scan Index (BSI) is a quantitative measurement of tumour burden in the skeleton calculated
from bone scan images. When analysed at the time of diagnosis, it has been shown to provide prognostic
information on survival in men with metastatic prostate cancer (PCa). In this study, we evaluated the prognostic
value of BSI during androgen deprivation therapy (ADT).
Methods: Prostate cancer patients who were at high risk of a poor outcome and who had undergone bone scan
at the time of diagnosis and during ADT were recruited from two university hospitals for a retrospective study. BSI
at baseline and follow-up were calculated using an automated software package (EXINIbonebsi). Associations
between BSI, other prognostic biomarkers and overall survival (OS) were evaluated using a Cox proportional
hazards regression model.
Results: One hundred forty-six PCa patients were included in the study. A total of 102 patient deaths were registered,
with a median survival time after the follow-up bone scan of 2.4 years (interquartile range (IQR) =0.8 to 4.4). Both at
baseline and during ADT, BSI was significantly associated with OS in univariate and multivariate analyses. When BSI was
added to a prognostic base model including age, prostate-specific antigen, clinical tumour stage and Gleason score,
the concordance index increased from 0.73 to 0.77 (p =0.0005) at baseline and from 0.77 to 0.82 (p <0.0001) during
ADT.
Conclusions: Automated BSI during ADT is an independent prognostic indicator of OS in PCa patients with bone
metastasis. It represents an emerging imaging biomarker that can be used in a prognostic model for risk stratification
of PCa patients at the time of diagnosis and at later stages of the disease. BSI could then help physicians identify
patients who could benefit from more aggressive therapies.
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Early diagnosis of prostate cancer (PCa) has increased
in recent decades, and the mortality rate has decreased
in countries where the prostate-specific antigen (PSA)
blood test was introduced at an early stage [1]. However,
in the management of patients at high risk of a poor
outcome, there is still an urgent need for improved
treatment and monitoring of the disease [1]. While
newly diagnosed low-risk patients have shown increas-
ing survival in various studies, patients at high risk of* Correspondence: mariana.reza@med.lu.se
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in any medium, provided the original work is prelapse after treatment still show low survival rates, a
result strongly associated with metastatic disease [2].
Evaluation of bone metastases is important in risk
stratification for optimum decision-making, as many
patients should be offered multimodality treatment. In
PCa patients with bone metastases, the current standard
primary treatment is androgen deprivation therapy
(ADT) and careful follow-up involving measurement of
serum testosterone and PSA [3]. In time, many patients
progress to a castration-resistant phase of the disease
(CRPC) with a subsequent need for second-line therapies
such as chemotherapy, new androgen-signalling blocking
agents and bone-targeting radioisotopes [4].Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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ment options for these patients - with encouraging re-
sults - there is an urgent need for predictive tools
before initiation of such treatments. It is perhaps even
more important to find objective and reproducible
tools for evaluation of response and to identify when
the treatment no longer has a desired effect. Despite
the increasing availability of advanced imaging modal-
ities such as magnetic resonance imaging (MRI) and
positron emission tomography/computed tomography
(PET/CT), bone scan (BS) is still the most commonly
used method of assessing metastatic spread to the skeleton
and monitoring response to treatment [5,6]. It has been
used for many years, but there is still no standardised way
of describing the images other than in vague terms, i.e.
the presence or absence of tumour spread to the skeleton
(M1 or M0).
Quantitative measurement of images can provide use-
ful information of clinical relevance, one example being
Bone Scan Index (BSI) - an imaging biomarker that
more objectively quantifies bone metastases as a per-
centage of the total skeletal mass affected by metastatic
disease [7]. BSI has been shown to contain prognostic
information in PCa patients with bone metastases [8],
but it has not yet been introduced in a clinical setting,
most probably because its calculation is time-consuming
and it requires an experienced reader. The recent devel-
opment of an automated method for calculation of BSITable 1 Patient characteristics (N =146)
Patient characteristics at baseline Values at baseline P
Age (years), median (IQR) (N =146) 68 (62 to 74) A
Baseline PSA (ng/mL), median (IQR) (N =146) 72 (20 to 187) F
Baseline BSI (N =146) F
BSI =0 (M0), N (%) 84 (57%) B
BSI >0 (M1), N (%) 62 (43%) B
BSI >0, median (IQR) 1.5 (0.2 to 4.2) B
Clinical T stage (N =131) B
T1, N (%) 9 (7%)
T2, N (%) 21 (16%)
T3, N (%) 85 (65%) B
T4, N (%) 16 (12%) H
Gleason score (N =135) B
5, N (%) 1 (0.7%) L
6, N (%) 6 (4.3%)
7, N (%) 48 (36%)
8, N (%) 36 (26%)
9, N (%) 39 (29%)
10, N (%) 5 (4%)
N, number of patients; IQR, interquartile range; BSI, Bone Scan Index; PSA, prostate-has provided us with a rapid and highly reproducible
method of obtaining information on tumour burden,
making it more attractive and feasible for routine clin-
ical use [9]. It has been demonstrated that automated
BSI correlates well with the manual method and is of
prognostic value in men with PCa metastases at the
time of diagnosis [9,10]. The value of a biomarker can
vary from one phase of disease to another, as with PSA,
which is of greater use in a screening situation and
during early phases of disease than in patients with
CRPC [11]. Although automated BSI has been proposed
as a prognostic biomarker at the time of diagnosis
[9,10], no data is available on its possible prognostic
value during ADT. In this study, we evaluated the value
of BSI as a biomarker for treatment response during
ADT in PCa patients.
Methods
Patient cohort
We retrospectively studied a series of consecutive PCa
patients who had undergone BS as part of the clinical
routine at Skåne University Hospital in Malmö from
1996 to 2010 and at Sahlgrenska University Hospital in
Gothenburg from 2002 to 2008 and were considered for in-
clusion. Baseline bone scans of patients from Sahlgrenska
University Hospital have also been used in a previous pub-
lication [10]. Patients meeting all the following inclusion
criteria were selected for the study:atient characteristics at follow-up Values at follow-up
ge (years), median (IQR) (N =146) 71 (65 to 77)
ollow-up PSA (ng/mL), median (IQR) (N =146) 23 (2.6 to 89)
ollow-up BSI (N =146)
SI =0 (M0), N (%) 55 (37%)
SI >0 (M1), N (%) 91 (63%)
SI >0, median (IQR) 1.7 (0.3 to 4.9)
SI change from baseline to follow-up (N =146)
SI increased:
igh BSI change, N (%) 67 (46%)
SI unchanged/decreased:
ow BSI change, N (%) 79 (54%)
specific antigen; M0, absence of metastasis; M1, presence of bone metastasis.
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least one of the following criteria in accordance
with the European Association of Urology
guidelines 2013 was met [6]: clinical tumour
stage (cT) T3/T4, biopsy Gleason score (GS)
8 to 10 or PSA concentration in blood
>20 ng/mL.
2. Availability of baseline scan: defined as whole-body
BS within 3 months of diagnosis and before
initiation of ADT.
3. Availability of follow-up scan: defined as whole-body
BS during hormonal treatment (>3.0 months after
start of treatment).
4. No treatment for PCa prior to baseline BS.
The study was performed in accordance with the
Declaration of Helsinki and was approved by the RegionalFigure 1 At baseline, Kaplan-Meier curves showing patient survi
patients included in the study were studied at the time of prostate
BSI values at baseline, these patients were stratified in three BSI cat
(n =32). These three groups demonstrated significantly different 5-ye
(p <0.0001).Ethical Review Boards at Lund University and Gothenburg
University, Sweden.
Bone scan
At both hospitals, whole-body BS was performed 2 to 4 h
after intravenous injection of 600 MBq technetium-99m
methylene diphosphonate (Tc-99m MDP) (Amersham
International plc, Amersham, UK). Anterior- and posterior-
view whole-body images were obtained using a gamma
camera equipped with low-energy, high-resolution, parallel-
hole collimators (MultiSPECT2 (Southern Scientific
Ltd., West Sussex, UK) or Siemens Symbia T (Siemens
Healthcare Diagnostics Inc. Deerfield, IL, USA) or Maxxus
(General Electric Medical Systems, Milwaukee, WI,
USA)), using a scan speed of 15 cm/min and a matrix
of 256 × 1024. Energy discrimination was provided by a
15% window centred on the 140 keV of Tc-99m.val probability stratified by BSI categories. All the 146
cancer diagnosis with bone scans. In accordance with their
egories: BSI =0 (n =84), BSI ≤1 (n =30) and BSI >1
ar survival rates of 80%, 60% and 25%, respectively
Table 2 Survival analysis demonstrating association
between age, PSA, cT, GS and BSI at baseline
Variable at baseline N Hazard ratio p value
Univariate analysis
Age 146 1.02 (0.99 to 1.05) 0.21
PSA 146 1.0002 (1.0000 to 1.0003) 0.02
cT 131 2.40 (1.43 to 4.04) 0.0009
GS 135 1.84 (1.38 to 2.46) <0.0001
BSI 146 1.27 (1.19 to 1.36) <0.0001
Multivariate analysis
Age 121 1.02 (0.98 to 1.06) 0.28
PSA 121 0.9999 (0.9998 to 1.0002) 0.80
cT 121 2.20 (1.28 to 3.78) 0.004
GS 121 1.86 (1.34 to 2.58) 0.0002
Multivariate analysis
Age 121 1.03 (0.99 to 1.06) 0.10
PSA 121 0.9999 (0.9997 to 1.0002) 0.58
cT 121 1.95 (1.16 to 3.28) 0.01
GS 121 1.99 (1.43 to 2.779) <0.0001
BSI 121 1.26 (1.16 to 1.37) <0.0001
PSA, prostate-specific antigen; cT, clinical stage; GS, Gleason score; BSI, Bone
Scan Index; N, number of patients.
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BSI, the measure of the total skeletal mass affected by
metastatic disease, was calculated using the software
EXINIbonebsi version 1.8 (EXINI Diagnostics AB, Lund,
Sweden). The automated method to calculate BSI,
which has been described in detail elsewhere [9], con-
sists of four steps. First, the different anatomical regions
of the skeleton such as the skull, ribs, vertebra and
pelvis are segmented. Second, hotspots are detected and
features describing them such as intensity, size, shape
and position are calculated. Third, artificial neural net-
works are used to classify each hotspot as metastatic
lesion or not based on the hotspot features. The neural
networks have been trained to mimic experienced readers
in distinguishing between metastatic lesions and benign
hotspots due to, for example, degenerative disease or
fracture. Fourth, the BSI is calculated as the sum of
volumetric fraction of the skeleton for all hotspots
classified as metastatic lesions.
Data collection
Retrospectively, clinical data at diagnosis, including
age, cT and GS, was collected from the medical re-
cords, as well as information on PSA concentration in
the blood both at diagnosis and at follow-up. Data on
survival was collected from the National Swedish
Population Registry. We defined overall survival (OS)
as the time from BS to death from any cause. All data
collected was anonymised and updated up to 31 December
2013.
Statistical analysis
The association between clinical stratification data
(age, cT, GS and PSA), BSI and OS was evaluated
using the Cox proportional hazards regression models,
using both univariate and multivariable modelling.
Hazard ratios (HR) together with 95% confidence in-
tervals were estimated, and discrimination between
the different survival models was assessed using the
concordance index (C-index). The significance of a
difference in C-index between different models was
calculated using the method described by Haibe-Kains
et al. [12].
Kaplan-Meier estimates of the survival function and
the log-rank test were used to indicate a significant
difference between groups stratified in accordance
with the BSI values. In the survival analysis, all data
was censored at a follow-up after 5 years. All analyses
were carried out using the R statistical computing
environment.
Results
A total of 146 PCa patients were included, and their
clinical-pathological characteristics are presented in Table 1.One hundred two patients out of the 146 died during the
follow-up, with a median survival time from the baseline
scan of 6 years (interquartile range (IQR) 3.5 to 8.4). The
group of 44 men who were still alive had a median follow-
up time from baseline BS of 7 years (IQR 6.4 to 11) and
from the follow-up BS of 4.7 years (IQR 3.5 to 7.1). The
median time between baseline and follow-up BS in the
entire group was 2.9 years (IQR 1.5 to 4.4), and patients
received ADT at the time of the follow-up scan for a
median of 2.2 years (IQR 1.2 to 4.0).
The androgen deprivation therapy administrated to
these patients in most cases comprised bicalutamide
(Casodex™, AstraZeneca plc, London, UK) or flutamide
(Eulexin™, Schering-Plough Corporation, Kenilworth,
NJ, USA), with or without a gonadotropin-releasing
hormone analogue (GNRH) agonist such as leuprorelin
(Eligard™, Enanton™ or Procren™) and goserelin acetate
(Zoladex®). Among the 146 patients, 18 (12%) received
anti-androgen monotherapy, whereas 128 (88%) received
combined androgen blockade.
Based on previously published data on the prognos-
tic value of BSI, we stratified the patients into three
groups based on their baseline BSI: BSI =0 (n =84),
BSI ≤1% (n =30) and BSI >1% (n =32), and we could
then demonstrate significantly different 5-year survival
rates of 80%, 60% and 25%, respectively (p <0.0001)
(Figure 1).
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GS were all significantly associated with OS (Table 2).
BSI showed the highest C-index (0.74), followed by GS
(0.67). In the multivariate analysis, BSI, cT and GS were
associated with OS, while PSA was not. The C-index
increased from 0.73 to 0.77 (p =0.0005) when adding
BSI to a base model including age, PSA, cT and GS.
Each one of the 146 patients was again retrospectively
analysed using a single follow-up BS for measurement of
BSI values during ADT. We decided to include only
follow-up BS obtained at more than 12 weeks from the
start of ADT, as suggested in The Prostate Cancer
Working Group 2 (PCWG2) guidelines when evaluating
BS after PCa treatment initiation [13]. During ADT, the
patients again showed different survival rates depending
on their BSI values when we stratified the patients into
the same three groups based on their follow-up BSI:
BSI =0 (n =55), BSI ≤1 (n =44) and BSI >1 (n =47).
These three groups displayed significantly different 5-yearFigure 2 At follow up, Kaplan-Meier curves showing patient survival
again studied with bone scans after the initiation of primary hormonal trea
were stratified in three BSI categories: BSI =0 (n =55), BSI ≤1 (n =44) and B
5-year survival rates of 92%, 57% and 20%, respectively (p <0.0001).survival rates of 92%, 57% and 20%, respectively (p <0.001)
(Figure 2).
In both univariate and the multivariate analyses at
follow-up, we included age, cT and GS at the time of
diagnosis and the corresponding follow-up values for
BSI and PSA. All these parameters were again associ-
ated with OS (Table 3). The C-index for BSI was again
the highest (0.80), this time followed by PSA (0.76).
The C-index increased from 0.77 to 0.83 (p <0.0001)
when adding BSI at follow-up to a model including
age, cT and GS (at the time of diagnosis) and PSA at
follow-up.
Among the 146 patients included in this study, 67
patients showed an increase in BSI from baseline to
follow-up (high BSI change). The remaining 79 patients
showed a decreased or a stable BSI value (low BSI
change). The OS rates were significantly different for
these two groups, showing 5-year survival rates of 41%
and 75%, respectively (p =0.0004) (Figure 3).probability stratified by BSI categories. These 146 patients were
tment. In accordance with their BSI values at follow-up, these patients
SI >1 (n =47). These three groups demonstrated significantly different
Table 3 Survival analysis demonstrating association
between age, PSA, cT, GS and BSI during ADT
Variable at follow-up N Hazard ratio p value
Univariate analysis
Age 146 1.04 (1.004 to 1.07) 0.03
PSA 146 1.0002 (1.00002 to 1.0003) 0.03
TS 131 2.39 (1.41 to 4.04) 0.001
GS 135 1.75 (1.32 to 2.32) 0.0001
BSI 146 1.26 (1.18 to 1.35) <0.0001
Multivariate analysis
Age 121 1.04 (1.0004 to 1.08) 0.03
PSA 121 1.0006 (1.0003 to 1.0009) <0.0001
TS 121 2.09 (1.24 to 3.51) 0.006
GS 121 1.70 (1.23 to 2.35) 0.001
Multivariate analysis
Age 121 1.05 (1.01 to 1.09) 0.009
PSA 121 1.0004 (1.00001 to 1.0008) 0.04
TS 121 1.98 (1.21 to 3.24) 0.007
GS 121 1.47 (1.04 to 2.08) 0.03
BSI 121 1.19 (1.09 to 1.29) <0.0001
PSA, prostate-specific antigen; cT, clinical stage; GS, Gleason score; BSI,
Bone Scan Index; ADT, androgen deprivation therapy; N, number
of patients.
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While the role of BSI at the time of diagnosis [10,11]
and during chemotherapy [14,15] has been described
in PCa patients, no data is available on the prognostic
additive value of BSI in high-risk PCa patients during
ADT. Prognostic evaluation of these patients is crucial
for optimal multimodality treatment, and our results
confirm that the addition of the imaging biomarker
BSI as a complement to classical prognostic markers
(as PSA, cT and GS) increases the predictive accuracy
of risk stratification in this group of patients. Changes
in PSA values during treatment constitute one of the
most used measures to study outcome in PCa patients,
but the isolated measure of this parameter has been
shown not to be of prognostic value when corrected
by BSI in patients with CRPC who are undergoing
chemotherapy [8]. Evaluation of the prognostic addi-
tive value of BSI in PCa patients during ADT was thus
of interest.
The results of the present study clearly show that BSI
is prognostic for OS during ADT, both as an isolated
measure and when added to a classical prognostic model
comprising age, PSA, cT and GS. The presence or ab-
sence of bone metastases (M1 or M0) is commonly used
to risk stratify PCa patients. We also showed that BSI, as
a quantitative measurement of the total tumour burden
in the skeleton, can be used to further stratify high-riskPCa patients with metastases. Patients with BSI <1 had
higher 5-year survival rates compared to those with
BSI >1, both at the time of diagnosis and during ADT
(Figures 1 and 2). PCa patients with distant metastases
at the time of diagnosis most commonly receive ADT
as primary treatment. The clinical implication of the
findings in our study is that BSI could be used as a
complement to conventional prognostic biomarkers in
the stratification of high-risk PCa patients in clinical
routine and in the design of clinical trials, not only at
the time of diagnosis but also during ADT. BSI could
then help physicians identify patients who could bene-
fit from more aggressive therapies (Figure 4).
In the present study, we have used OS as an endpoint
for outcome analysis. Prostate cancer specific survival
would also have been important to evaluate, but due to
limited availability of data, this endpoint could not be
used. In future prospective BSI studies, we plan to investi-
gate additional endpoints besides OS such as biochemical
recurrence, clinical progression and radiographic progres-
sion. It would be also of value to evaluate the correlation
of BSI with other prognostic biomarkers that showed
impact on survival in PCa patients. Therefore, beside
the previous studied parameters, we intend to include
alkaline phosphatase, haemoglobin, lactate dehydrogen-
ase and performance status in the design of our future
prospective studies.
We have retrospectively evaluated a consecutive
cohort of prostate cancer patients who underwent
whole-body scan examinations both at the time of
diagnosis and later on at follow-up after hormonal
therapy according to the standard-of-care procedure.
At our centres, the indications for bone scan examina-
tions in prostate cancer patients are mainly PSA in
blood >20 and/or high GS (>8), increasing PSA values
(biochemical progression) and bone pain (symptomatic
progression). These indications may increase the possi-
bility of finding bone metastasis already at the time of
diagnosis and or progression of disease at follow-up
in patients who underwent whole-body scan examina-
tions at our nuclear medicine departments, but to
avoid the risk of selection bias, this patient material
represents a consecutive cohort.
BSI is advantageous in that it is based on BS exami-
nations, which constitute the most widely used method
of evaluating metastatic spread to the bone in PCa pa-
tients, as considered to be a golden standard [6]. More
advanced imaging modalities such as MRI and PET/
CT are still not commonly used and they are, to some
extent, hampered by the lack of standardization. A dis-
advantage of BSI is the limitations of the BS technique
itself, e.g. the difficulty of distinguish between flare
reactions and disease progress after initiation of treat-
ment. This is most common during the first 3 months
Figure 3 At follow-up, Kaplan-Meier curves showing patient survival probability stratified by BSI changes categories. BSI
changes from baseline to follow-up were evaluated among the 146 patients studied. In accordance with their BSI change values at
follow-up, these patients were classified in two BSI changes categories: High BSI change (BSI increase n =67) and low BSI change
(stable BSI or BSI decrease, n =79). These two groups demonstrated significantly different 5-year survival rates of 41% and 75%,
respectively (p =0.0004).
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tients who had undergone baseline scans before initial
treatment as well as follow-up scans more than 12
weeks after commencement of ADT, as suggested in
the PCWG2 guidelines when evaluating BS after PCa
treatment initiation [13]. Despite these cautions to
reduce the probability of flare effect during the study
design, as well as the fact that there were no signs
suggesting its presence in the visual evaluation of the
BS images studied (an increase in activity of previously
seen metastatic lesions and no new lesions), we cannot
ensure the total exclusion of the phenomenon in this
material. At present, there is no method that can effect-
ively ensure its exclusion at follow-up. Inclusion of a flare
reaction would weaken the association between BSI and
OS, since patients with a positive response to treatment
and a falsely elevated BSI would most probably have a
better prognosis.BS imaging is a very sensitive technic for osteoblastic
bone reactions. An intense uptake in a BS does not al-
ways correlate with metastatic disease. These changes
can be also found in benign pathologies such as osteomye-
litis and fractures. BSI refers to percentage of skeleton
affected only by tumour; we have therefore reviewed each
BSI measurement and corrected manually those lesions of
benign nature that were misclassified as hotspots. This
correction though was only needed in less than 5% of the
cases.
In the process of implementing BSI as an imaging bio-
marker for PCa patients, we here add new and important
information on the value of BSI during ADT. Further
studies on BSI as a clinically useful biomarker to predict
and to evaluate response to novel treatments in CRPC are
also underway. BSI studies could be of great value to strat-
ify patients in clinical trials and to measure clinical efficacy
of new treatments.
Figure 4 BSI progression in a metastatic hormone-resistant prostate cancer patient. This figure shows posterior views of baseline (A) and
follow-up (B) whole-body bone scans of a metastatic hormone-resistant prostate cancer patient. Hot spots, presented in red, represent the bone
area affected by tumour. The BSI change from baseline to follow-up shows BSI progression in accordance with patient's high BSI change after
androgen deprivation therapy. According to our results, high BSI changes are significantly associated with poorer prognosis.
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We conclude that BSI during ADT is independently as-
sociated with OS. This new imaging biomarker can be
used as a complement to conventional prognostic bio-
markers such as PSA, GS and cT to stratify high-risk
prostate cancer patients, not only at the time of diagno-
sis but also during later stages of the disease. BSI could
then help physicians identify patients who could benefit
from more aggressive therapies.Competing interests
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